Quick HBV 5-1 Test
|FOB Unit Price:||US $1 US $0.1|
|Purchase Qty. (Pieces)||FOB Unit Price|
|Production Capacity:||50, 000, 000/Year|
|Transport Package:||Single Pack|
|Payment Terms:||L/C, T/T|
- Model NO.: YX-XMBS-006
- Application: for Diagnosis
- 1 Test/Pouch: 25tests/Kit
- Specification: CE
- Type: Biological Diagnostic Reagents
- Form: Strip
- Trademark: SURECARE
- Origin: China
Detection of HBsAg, HIV I&II, HCV Ab.
HBsAg/ HIV I&II /HCV Panel Test Card
FOR THE QUALITATIVE ASSESSMENT OF HBSAG, HIV I&II ANTIBODIES AND HCV ANTIBODY IN HUMAN SERUM, PLASMA OR WHOLE BLOOD
HBsAg/ HIV I&II /HCV Panel Test Card, is an immunochromatography assay for the qualitative detection of Hepatitis B virus surface antigen (HBsAg), antibodies to Human Immunodeficiency Viruses(HIV I&II), antibodies against hepatitis C virus (HCV Ab) in human serum, plasma or whole blood.
HBsAg Test: HBsAg Test showed equivalent detectability to commercially available EIA for HBsAg. A result of 99.17% correlation with EIA was obtained from a clinical study of 1071 specimens.
HIV I&II Test: In a clinical evaluation of the performance of HIV I&II Test using 2567 confirmed negative and 510 positive samples, sensitivity was 99.6% (508/510) and specificity was 99.7% (2560/2567). The overall agreement with the reference ELISA tests is 99.7%.
HIV positive sera
HIV negative sera
The precision of three lots tested with Chinese FDA QC panel showed 100% agreement.
In order to check possible interferences with potentially cross-reactive sera, an independent evaluation was performed with one hundred samples. The variety of sera samples containing possibly interfering substances were tested and found no interfering with Rapid HIV I&II Test.
Number of samples tested
HIV I&II Test
Acute Hepatitis A
Hepatitis A Recovery Phase
Infectious disease with non hepatitis B
HBsAg, HBeAg and HBcAb Positive
Clinical Specificity: A blood donor population of 2948 individuals was tested negative with 3 different kits from different manufacturers. The specificity of Rapid HCV Ab test was 99.55%.
Clinical Sensitivity: Among 480 clinical hepatitis C patients confirmed positive by RIBA 3.0, 479 were positive when tested with Rapid HCV Ab test. The sensitivity was 99.79%.
No cross reactivity was observed with specimens from patients infected with HAV, HBV, HIV, HTLV, CMV, and TP.